Profiling prostate biology | Science

Profiling prostate biology | Science: Molecular profiling of heterogeneous cell populations at the single-cell level using single-cell RNA sequencing (scRNA-seq) has provided refined cell type–specific gene expression signatures and allowed the discovery of rare cell types. Applying such an approach in the context of anatomy and pathology informs disease mechanisms. A requirement for androgen is a cardinal feature in the development and maintenance of normal prostate and for the maintenance of prostate adenocarcinoma ([ 1 ][1]). On page 497 of this issue, Karthaus et al. ([ 2 ][2]) provide an in-depth characterization of prostatic cellular heterogeneity and address mechanisms of androgen independence in regenerating mouse prostates. They identify an adaptive stemlike phenotype in a large population of secretory epithelial cells undergoing androgen-dependent regeneration, uncovering an unappreciated plasticity in these differentiated cells, which has implications for prostate cancer therapy.

Prostate epithelium consists of three primary cell types: luminal cells, an underlying layer of basal cells, and rare neuropeptide-secreting neuroendocrine cells. Luminal cells express the androgen receptor (AR) transcription facto

Telemedicine: Tips for your Appointment — Cancer ABCs

Telemedicine: Tips for your Appointment — Cancer ABCs: Have a virtual doctor's visit coming up? Follow these tips to make the most of it.

Axumin-based PET/CT scans and detection of recurrent prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK

Axumin-based PET/CT scans and detection of recurrent prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK: A new report from a relatively small, single-institution study has provided additional information about the utility of [18F]fluciclovine (Axumin) PET/CT scans in the detection of recurrent prostat…

Major trial shows breast cancer drug can hit prostate cancer Achilles heel -- ScienceDaily

Major trial shows breast cancer drug can hit prostate cancer Achilles heel -- ScienceDaily: A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports. Olaparib, a pill lacking the side effects of chemotherapy, can target an Achilles heel in prostate cancers with a weakness in their ability to repair damaged DNA.

'Bold' Prostate Cancer Trial Enrolls 'Very, Very Quickly'

'Bold' Prostate Cancer Trial Enrolls 'Very, Very Quickly': For men with early prostate cancer on active surveillance, can the immunotherapy sipuleucel-T (Provenge) reduce grade progression?

More negative data for checkpoint inhibition in treatment of mCRPC | THE "NEW" PROSTATE CANCER INFOLINK

More negative data for checkpoint inhibition in treatment of mCRPC | THE "NEW" PROSTATE CANCER INFOLINK: Alas … once again we hear that the combination of  androgen receptor blockade (with enzalutamide/Xtandi) + a checkpoint inhibitor (the PD-L1 inhibitor atezolizumab/Tecentriq) has had no clini…

Breast cancer drug slows prostate cancer progression in major trial

Breast cancer drug slows prostate cancer progression in major trial: Scientists are reporting some promising findings from a large prostate cancer trial, where patients were administered a drug typically used to treat breast cancer. The drug proved more effective than standard hormone treatments at applying the brakes to the disease, with the scientists hopeful it…

It's a Bust: Adding Immunotherapy No Benefit in mCRPC

It's a Bust: Adding Immunotherapy No Benefit in mCRPC: The immune checkpoint inhibitor atezolizumab was added to standard treatment with enzalutamide in men with metatastic castration-resistant prostate cancer.

Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM

Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM: Original Article from The New England Journal of Medicine — Olaparib for Metastatic Castration-Resistant Prostate Cancer

Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance | Cancer Research

Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance | Cancer Research: In incurable castration-resistant prostate cancer (CRPC), resistance to the novel androgen receptor (AR) antagonist enzalutamide (ENZ) is driven mainly by AR overexpression. Here we report that the expression of interferon regulatory factor 8 (IRF8) is increased in primary prostate cancer (PCa) but decreased in CRPC compared to normal prostate tissue. Decreased expression of IRF8 positively associated with CRPC progression and ENZ resistance. IRF8 interacted with AR and promoted its degradation via activation of the ubiquitin/proteasome systems. Epigenetic knockdown of IRF8 promoted AR-mediated PCa progression and ENZ resistance in vitro and in vivo. Furthermore, IFNα increased expression of IRF8 and improved the efficacy of ENZ in CRPC by targeting the IRF8-AR axis. We also provide preliminary evidence for the efficacy of IFNα with hormonotherapy in a clinical study. Collectively, this study identifies IRF8 both as a tumor suppressor in PCa pathogenesis and a potential alternative therapeutic option to overcome ENZ resistance.

Using 2 Prostate Biopsy Techniques Optimizes Cancer Diagnosis | Oncology | JAMA | JAMA Network

Using 2 Prostate Biopsy Techniques Optimizes Cancer Diagnosis | Oncology | JAMA | JAMA Network: Combining a traditional biopsy with a magnetic resonance imaging (MRI)–targeted biopsy more accurately diagnoses clinically significant prostate cancer than either technique alone, according to a recent study by National Institutes of Health (NIH) researchers.

New radiation therapies keep advanced prostate cancer in check - Harvard Health Blog - Harvard Health Publishing

New radiation therapies keep advanced prostate cancer in check - Harvard Health Blog - Harvard Health Publishing: Treatments for prostate cancer are always evolving, and now research is pointing to new ways of treating a cancer that has just begun to spread, or metastasize, after initial surgery or radiation. Doctors usually give hormonal therapies in these cases to block testosterone, which is a hormone that makes the cancer grow faster. But newer …

Olaparib in treatment of men with mCRPC and selected HRR gene mutations | THE "NEW" PROSTATE CANCER INFOLINK

Olaparib in treatment of men with mCRPC and selected HRR gene mutations | THE "NEW" PROSTATE CANCER INFOLINK: According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … ove…

Clinical Challenges: Nuclear Medicine and Biochemically Recurrent Prostate Cancer | MedPage Today

Clinical Challenges: Nuclear Medicine and Biochemically Recurrent Prostate Cancer | MedPage Today: With the advent of fluciclovine and PSMA, nuclear medicine has carved out a key role in the visualization of prostate cancer

Prostate cancer death rates predicted to fall this year by 9.5% on the 2015 figure, research shows | Daily Mail Online

Prostate cancer death rates predicted to fall this year by 9.5% on the 2015 figure, research shows | Daily Mail Online: Prostate death rates are expected to fall this year because of better diagnosis and treatment, research suggests. British death rates will be 9.5 per cent lower for 2020 than in 2015, according to a study.